ClinicalTrials.gg
CompletedNCT02572947MONODOUpdated Nov 1, 2017

A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients

A Phase 2 interventional study of Dolutegravir in Human Immunodeficiency Virus, Dolutegravir and Monotherapy, sponsored by Calmy Alexandra. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-01.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Calmy Alexandra · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Current HIV treatment guidelines recommend a combination of drugs for the maintenance of antiretroviral therapy (ART). Simplification is considered critical to further scale-up of treatment, to support retention in care and to reduce costs. Dolutegravir is a once daily integrase inhibitor that shows very good tolerability, efficacy, and distinctive resistance profile. The researchers aim at investigating the feasibility of dolutegravir monotherapy in maintenance therapy. Briefly, 10 virologically suppressed patients for at least six months on conventional triple ART of dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs) will be switched to dolutegravir monotherapy for 24 weeks. The primary endpoint is the number of patients completing 24 weeks of dolutegravir monotherapy without experiencing virological failure.

02

Conditions studied

  • Human Immunodeficiency Virus
  • Dolutegravir
  • Monotherapy
  • Treatment Efficacy

Browse trials for

Keywords

  • Dolutegravir
  • HIV infection
  • Anti-Retroviral Agents
  • HIV Integrase Inhibitors
  • Integrase Inhibitors
  • Pharmacologic Actions
  • Therapeutic Uses
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 8 is below the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

Calmy Alexandra is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infection;
  • Patient included in the Swiss HIV Cohort Study (SHCS);
  • ≥ 18 years of age;
  • Virologically suppressed for at least 24 months on triple ART (changes for toxicity permitted) with at least 4 HIV-1 RNA measurements in plasma \<50 copies/ml;
  • No history of previous failure on ART;
  • No documented antiretroviral drugs resistance;
  • No co-infection with or C virus;
  • Effective in women;
  • Willing to provide CSF and semen samples;
  • Written

Exclusion criteria

Exclusion Criteria:

  • -2 infection;
  • Renal dysfunction ( \<50ml/min);
  • or alanine aminotransferase >5x upper limit normal;
  • Concomitant use of carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St John's wort, rifampicin or metformin;
  • Previous AIDS defining conditions or active in the past five years;
  • Positive HIV viral load in CSF at baseline;
  • Known or suspected non-compliance;
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Dolutegravir monotherapy

    10 patients will be simplified to monotherapy of dolutegravir tablet 50mg once daily for 24 weeks

    Drug: Dolutegravir

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients without virological failure defined as plasma HIV-1 RNA ≥ 200 copies/ml on two consecutive measurements or positive HIV-1 RNA level in cerebrospinal fluid (CSF) at week 24 or before

    Time frame: week 24

Secondary outcomes

  1. Quantification of the HIV-1 DNA reservoir in peripheral blood monocyte cells at baseline and week 24

    Time frame: week 24

  2. Emergence of genotypic resistance in plasma HIV-1 RNA in case of virological failure

    Time frame: week 24

  3. Quantification HIV-1 RNA levels in the CSF and semen at baseline and week 24

    Lumbar puncture is optional at baseline

    Time frame: week 24

  4. Change from baseline CD4 cell count from baseline at week 24

    Time frame: week 24

  5. Adherence to medication at weeks 4, 8, 12, 16, 20, 24

    Number of participants with suboptimal adherence defined as more than 3 pills (10%) remaining from previous monthly visit OR missed more than one dose in a row OR missed dose more than once every two weeks

    Time frame: week 24

  6. Lipidic profile changes from baseline at week 24

    Time frame: week 24

  7. Body fat composition as measured by dual energy x-ray absorptiometry (DXA) scan at baseline and week 24

    Time frame: week 24

  8. Change in bone mineral density from baseline to week 24

    Number of patients with normal bone density, osteopenia or osteoporosis as defined by DXA scans results

    Time frame: week 24

Other outcomes

  1. Change in immune activation from baseline to week 24 measured by highly sensitive C-reactive protein (mg/l)

    Time frame: week 24

  2. Change in immune activation from baseline to week 24 measured by cytokines (pg/ml)

    Time frame: week 24

  3. Change in immune activation from baseline to week 24 measured by d-dimers (microg/l)

    Time frame: week 24

07

Study locations

1 site
  • University Hospitals of Geneva, HIV unit
    Geneva, 1205, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2016, a primary completion of Jun 2017 and a completion of Sep 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2015
First posted
Oct 9, 2015
Start
Jun 2016
Primary completionActual
Jun 2017
CompletionActual
Sep 2017
Last update
Nov 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02572947
Lead sponsor
Calmy Alexandra
Responsible party
Calmy Alexandra (Médecin adjointe agrégée, HIV Unit director, Infectious Diseases Division, University Hospital, Geneva) — Sponsor-investigator
First posted
Oct 9, 2015
Start date
Jun 2016
Primary completion
Jun 2017
Completion
Sep 2017
Last update
Nov 1, 2017

Study contacts

Delphine Sculier, MD
principal investigator · University Hospital, Geneva

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion